Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 14 studies | 24% ± 7% | |
T cell | 10 studies | 22% ± 9% | |
CD8-positive, alpha-beta T cell | 8 studies | 21% ± 6% | |
mature NK T cell | 7 studies | 19% ± 2% | |
CD8-positive, alpha-beta memory T cell | 7 studies | 25% ± 6% | |
mast cell | 6 studies | 19% ± 3% | |
CD16-positive, CD56-dim natural killer cell, human | 6 studies | 22% ± 6% | |
endothelial cell | 6 studies | 20% ± 2% | |
fibroblast | 6 studies | 21% ± 4% | |
effector memory CD8-positive, alpha-beta T cell | 5 studies | 24% ± 10% | |
gamma-delta T cell | 5 studies | 26% ± 8% | |
classical monocyte | 4 studies | 24% ± 3% | |
conventional dendritic cell | 4 studies | 26% ± 7% | |
myeloid cell | 4 studies | 22% ± 6% | |
epithelial cell | 4 studies | 30% ± 16% | |
smooth muscle cell | 4 studies | 18% ± 3% | |
leukocyte | 3 studies | 20% ± 4% | |
naive thymus-derived CD8-positive, alpha-beta T cell | 3 studies | 20% ± 3% | |
mucosal invariant T cell | 3 studies | 29% ± 4% | |
innate lymphoid cell | 3 studies | 21% ± 2% | |
CD16-negative, CD56-bright natural killer cell, human | 3 studies | 24% ± 3% | |
macrophage | 3 studies | 22% ± 5% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 5 studies | 20% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2765.83 | 1445 / 1445 | 100% | 13.53 | 183 / 183 |
lung | 100% | 2763.03 | 578 / 578 | 100% | 15.90 | 1155 / 1155 |
stomach | 100% | 2115.53 | 359 / 359 | 100% | 14.84 | 286 / 286 |
skin | 100% | 1783.40 | 1806 / 1809 | 100% | 19.69 | 472 / 472 |
prostate | 100% | 2444.40 | 245 / 245 | 100% | 15.54 | 501 / 502 |
uterus | 100% | 2323.04 | 170 / 170 | 100% | 19.90 | 458 / 459 |
pancreas | 100% | 1190.94 | 327 / 328 | 100% | 18.47 | 178 / 178 |
intestine | 100% | 2805.04 | 966 / 966 | 100% | 16.20 | 525 / 527 |
bladder | 100% | 2773.71 | 21 / 21 | 100% | 17.32 | 502 / 504 |
kidney | 100% | 1808.61 | 89 / 89 | 100% | 14.42 | 897 / 901 |
breast | 100% | 2087.88 | 459 / 459 | 99% | 15.17 | 1111 / 1118 |
thymus | 100% | 1972.98 | 652 / 653 | 100% | 11.67 | 602 / 605 |
brain | 99% | 2091.82 | 2622 / 2642 | 100% | 17.33 | 705 / 705 |
ovary | 100% | 2609.21 | 180 / 180 | 99% | 9.20 | 425 / 430 |
adrenal gland | 100% | 2705.74 | 258 / 258 | 99% | 19.02 | 227 / 230 |
liver | 99% | 1174.16 | 224 / 226 | 100% | 11.90 | 404 / 406 |
lymph node | 0% | 0 | 0 / 0 | 100% | 22.36 | 29 / 29 |
muscle | 100% | 3744.36 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2597.99 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 16.27 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 7.39 | 1 / 1 |
blood vessel | 100% | 3060.48 | 1334 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 2383.67 | 1203 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 4405.48 | 927 / 929 | 0% | 0 | 0 / 0 |
heart | 99% | 3512.86 | 855 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 95% | 8.79 | 76 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0140694 | Biological process | non-membrane-bounded organelle assembly |
GO_0051260 | Biological process | protein homooligomerization |
GO_0032463 | Biological process | negative regulation of protein homooligomerization |
GO_0048821 | Biological process | erythrocyte development |
GO_0042116 | Biological process | macrophage activation |
GO_0030324 | Biological process | lung development |
GO_0006397 | Biological process | mRNA processing |
GO_0007507 | Biological process | heart development |
GO_0001822 | Biological process | kidney development |
GO_0060041 | Biological process | retina development in camera-type eye |
GO_0006338 | Biological process | chromatin remodeling |
GO_0002040 | Biological process | sprouting angiogenesis |
GO_0033077 | Biological process | T cell differentiation in thymus |
GO_0008380 | Biological process | RNA splicing |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0048024 | Biological process | regulation of mRNA splicing, via spliceosome |
GO_0006909 | Biological process | phagocytosis |
GO_0035513 | Biological process | oxidative RNA demethylation |
GO_0043654 | Biological process | recognition of apoptotic cell |
GO_0018395 | Biological process | peptidyl-lysine hydroxylation to 5-hydroxy-L-lysine |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0005730 | Cellular component | nucleolus |
GO_0005886 | Cellular component | plasma membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_1990904 | Cellular component | ribonucleoprotein complex |
GO_0005634 | Cellular component | nucleus |
GO_0038023 | Molecular function | signaling receptor activity |
GO_0070815 | Molecular function | peptidyl-lysine 5-dioxygenase activity |
GO_0003727 | Molecular function | single-stranded RNA binding |
GO_0033749 | Molecular function | histone H4R3 demethylase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0106140 | Molecular function | P-TEFb complex binding |
GO_0035515 | Molecular function | oxidative RNA demethylase activity |
GO_0032452 | Molecular function | histone demethylase activity |
GO_0005506 | Molecular function | iron ion binding |
GO_0140537 | Molecular function | transcription regulator activator activity |
GO_0003723 | Molecular function | RNA binding |
GO_0140457 | Molecular function | protein demethylase activity |
GO_0033746 | Molecular function | histone H3R2 demethylase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | JMJD6 |
Protein name | Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6 (Histone arginine demethylase JMJD6) (JmjC domain-containing protein 6) (Jumonji domain-containing protein 6) (Lysyl-hydroxylase JMJD6) (Peptide-lysine 5-dioxygenase JMJD6) (Phosphatidylserine receptor) Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6 (EC 1.14.11.-) (Histone arginine demethylase JMJD6) (JmjC domain-containing protein 6) (Jumonji domain-containing protein 6) (Lysyl-hydroxylase JMJD6) (Peptide-lysine 5-dioxygenase JMJD6) (Phosphatidylserine receptor) (Protein PTDSR) |
Synonyms | KIAA0585 hCG_30900 PTDSR PSR |
Description | FUNCTION: Dioxygenase that can both act as a arginine demethylase and a lysyl-hydroxylase . Acts as a lysyl-hydroxylase that catalyzes 5-hydroxylation on specific lysine residues of target proteins such as U2AF2/U2AF65 and LUC7L2. Regulates RNA splicing by mediating 5-hydroxylation of U2AF2/U2AF65, affecting the pre-mRNA splicing activity of U2AF2/U2AF65 . Hydroxylates its own N-terminus, which is required for homooligomerization . Plays a role in the regulation of nucleolar liquid-liquid phase separation (LLPS) by post-translationally modifying LIAT1 at its lysine-rich domain which inhibits LIAT1 nucleolar targeting (By similarity). In addition to peptidyl-lysine 5-dioxygenase activity, may act as an RNA hydroxylase, as suggested by its ability to bind single strand RNA . Also acts as an arginine demethylase which preferentially demethylates asymmetric dimethylation . Demethylates histone H3 at 'Arg-2' (H3R2me) and histone H4 at 'Arg-3' (H4R3me), including mono-, symmetric di- and asymmetric dimethylated forms, thereby playing a role in histone code . However, histone arginine demethylation may not constitute the primary activity in vivo . In collaboration with BRD4, interacts with the positive transcription elongation factor b (P-TEFb) complex in its active form to regulate polymerase II promoter-proximal pause release for transcriptional activation of a large cohort of genes. On distal enhancers, so called anti-pause enhancers, demethylates both histone H4R3me2 and the methyl cap of 7SKsnRNA leading to the dismissal of the 7SKsnRNA:HEXIM1 inhibitor complex. After removal of repressive marks, the complex BRD4:JMJD6 attract and retain the P-TEFb complex on chromatin, leading to its activation, promoter-proximal polymerase II pause release, and transcriptional activation . Demethylates other arginine methylated-proteins such as ESR1 . Has no histone lysine demethylase activity . Required for differentiation of multiple organs during embryogenesis. Acts as a key regulator of hematopoietic differentiation: required for angiogenic sprouting by regulating the pre-mRNA splicing activity of U2AF2/U2AF65 (By similarity). Seems to be necessary for the regulation of macrophage cytokine responses . . |
Accessions | Q6NYC1 ENST00000585429.1 ENST00000542934.5 ENST00000303996.10 A0A0S2PZM4 K7EJU9 B2WTI3 ENST00000445478.6 [Q6NYC1-3] ENST00000617192.4 B2WTI4 ENST00000397625.9 [Q6NYC1-1] |